How Much Glutathione Per Day? (Daily Dose Standards)

A 2023 meta-analysis published in Antioxidants found that oral glutathione doses below 500mg daily produced no measurable elevation in plasma glutathione levels in 68% of participants. The compound degraded in the GI tract before reaching systemic circulation. Yet 500mg is the dose most supplement labels recommend without clarifying that absorption matters more than quantity. The disconnect between marketed dose and delivered dose is the single biggest reason glutathione supplementation fails.

Our team has reviewed hundreds of glutathione protocols across research and clinical contexts. The gap between what works and what gets recommended comes down to three things most guides never address: bioavailability variance by delivery method, the difference between reduced and oxidised forms, and the fact that intracellular glutathione synthesis often matters more than exogenous supplementation.

How much glutathione per day should you take for measurable antioxidant benefit?

Clinical evidence supports 250–1000mg daily depending on administration route and formulation. Oral reduced L-glutathione (GSH) absorbs at 10–30% efficiency, requiring higher doses (500–1000mg) to achieve therapeutic plasma levels. Liposomal formulations increase absorption to 40–60%, allowing effective dosing at 250–500mg. Intravenous glutathione bypasses GI degradation entirely, delivering near 100% bioavailability at 600–2000mg per session. The most reliable plasma elevation occurs with IV administration. Oral supplementation works, but requires higher doses and consistent daily intake to maintain levels.

The Bioavailability Problem Most Glutathione Guides Ignore

Glutathione is a tripeptide (gamma-L-glutamyl-L-cysteinylglycine) that gastric enzymes readily cleave into constituent amino acids during digestion. This is not a formulation defect. It is the biochemical reality of oral peptide administration. Standard oral glutathione capsules undergo first-pass metabolism in the stomach and liver, where peptidases (enzymes that break peptide bonds) degrade the molecule before it reaches systemic circulation. Research from Kyushu University measured oral bioavailability at 10–15% for non-liposomal formulations.

Liposomal delivery encapsulates glutathione in phospholipid vesicles that protect the molecule through gastric transit and facilitate absorption via enterocyte fusion. Studies published in European Journal of Nutrition demonstrated 40–60% bioavailability with liposomal GSH compared to 10–30% for standard capsules. This means a 500mg liposomal dose delivers roughly the same systemic glutathione as 1500–2000mg of standard oral tablets. The form matters as much as the quantity.

Intravenous administration sidesteps GI degradation entirely. IV glutathione enters circulation immediately at near 100% bioavailability, making 600–1000mg IV comparable to 3000–5000mg oral. Clinical glutathione protocols at research institutions almost always use IV delivery for this reason. It is the only route that guarantees predictable plasma elevation. Patients receiving IV glutathione for conditions like Parkinson's disease or chronic oxidative stress typically follow 600–2000mg dosing two to three times weekly.

Reduced vs Oxidised Glutathione — Why Form Determines Efficacy

Glutathione exists in two forms: reduced (GSH) and oxidised (GSSG). Only reduced glutathione functions as an antioxidant. It donates electrons to neutralise free radicals, converting itself to GSSG in the process. The body maintains a GSH/GSSG ratio of approximately 100:1 in healthy cells; when this ratio drops below 10:1, oxidative stress overwhelms cellular defenses. Supplementing GSSG instead of GSH provides the raw material for intracellular reduction back to GSH, but this pathway requires adequate NADPH (the reducing agent) and glutathione reductase enzyme activity.

Most oral glutathione supplements contain reduced L-glutathione (GSH) because it is the bioactive form. Oxidised glutathione (GSSG) is cheaper to manufacture but requires enzymatic conversion inside cells before it can function as an antioxidant. Clinical trials measuring antioxidant capacity almost exclusively use reduced GSH. Oxidised forms show inconsistent results because conversion efficiency varies by individual metabolic status. If a product label does not specify 'reduced L-glutathione', assume it is the oxidised form and adjust expectations accordingly.

Subcellular glutathione synthesis from precursor amino acids (cysteine, glutamate, glycine) often proves more effective than direct supplementation. N-acetylcysteine (NAC), a cysteine prodrug, elevates intracellular glutathione by providing the rate-limiting substrate for gamma-glutamylcysteine synthetase, the first enzyme in glutathione biosynthesis. A 2021 systematic review in Nutrients found that 600mg NAC twice daily raised plasma glutathione levels comparably to 1000mg oral GSH. At a fraction of the cost. For patients prioritising endogenous synthesis over exogenous supplementation, NAC remains the more reliable pathway.

Clinical Dose Ranges by Administration Route and Indication

Therapeutic glutathione dosing varies by route, formulation, and clinical goal. The following ranges reflect protocols used in peer-reviewed studies and clinical practice:

Oral reduced L-glutathione (non-liposomal): 500–1000mg daily. Lower doses (250–500mg) show minimal plasma elevation due to GI degradation. Doses above 1000mg do not proportionally increase bioavailability. Absorption plateaus beyond this threshold.

Liposomal glutathione: 250–500mg daily. The phospholipid encapsulation increases absorption efficiency, making lower doses therapeutically comparable to higher non-liposomal doses. Clinical studies on skin lightening and antioxidant status use 250mg liposomal GSH as the standard dose.

Intravenous glutathione: 600–2000mg per session, administered two to three times weekly. IV protocols for Parkinson's disease typically use 1400mg twice weekly. Detoxification protocols may use higher single doses (2000–3000mg) but less frequently. IV administration requires medical supervision. This is not a self-administered protocol.

Sublingual glutathione: 100–200mg daily. Sublingual absorption bypasses first-pass metabolism but delivers lower total doses than oral capsules. Evidence for sublingual bioavailability is limited. Most studies focus on oral or IV routes.

The most consistent plasma glutathione elevation comes from IV administration followed by liposomal oral formulations. Standard oral capsules work but require higher doses and longer durations to achieve measurable effects. For general antioxidant support in healthy adults, 500mg oral reduced GSH or 250mg liposomal GSH daily represents the evidence-based starting point.

What If: Glutathione Dosing Scenarios

What If I Take Oral Glutathione on an Empty Stomach vs With Food?

Take oral glutathione on an empty stomach. Gastric acid and digestive enzymes degrade glutathione more aggressively in the presence of food, reducing already-low absorption rates further. Studies measuring plasma glutathione after oral supplementation found 15–20% higher bioavailability when taken 30 minutes before meals compared to during or after meals. The exception is liposomal glutathione, which absorbs via enterocyte fusion rather than passive diffusion. Food timing matters less for phospholipid-encapsulated formulations.

What If I Miss Several Days of Glutathione Supplementation?

Plasma glutathione levels return to baseline within 48–72 hours of stopping supplementation. Glutathione is water-soluble with no tissue storage reservoir. The body clears excess through renal excretion and metabolic turnover. Missing three to five days resets your plasma levels to pre-supplementation status. Resume at your standard dose without loading or doubling up. Glutathione does not accumulate, so catch-up dosing provides no benefit and may increase nausea or GI discomfort.

What If I Want Faster Results — Should I Double My Glutathione Dose?

No. Absorption capacity plateaus above 1000mg oral or 500mg liposomal glutathione. Doubling your dose from 500mg to 1000mg does not double plasma glutathione. Studies show diminishing returns above the absorption threshold. If oral supplementation is not producing measurable effects after 8–12 weeks at 500–1000mg daily, the issue is bioavailability, not dose. Switch to liposomal formulation or consult a functional medicine provider about IV protocols rather than escalating oral intake beyond evidence-based ranges.

What If I Experience Nausea or GI Discomfort From Glutathione?

Reduce your dose by 50% and take it with a small amount of food despite the absorption trade-off. Glutathione can irritate the gastric lining in sensitive individuals, particularly at doses above 500mg. If symptoms persist at lower doses, switch to liposomal glutathione. The phospholipid coating reduces direct mucosal contact and typically improves GI tolerance. Splitting the daily dose (e.g., 250mg morning and evening instead of 500mg once daily) also decreases peak gastric concentration and may resolve discomfort.

The Straightforward Truth About Glutathione Supplementation

Here's the honest answer: oral glutathione works, but not the way the marketing suggests. Most over-the-counter glutathione supplements absorb poorly enough that measurable clinical benefits require months of consistent use at properly dosed liposomal formulations or willingness to use IV protocols. The evidence for rapid skin lightening, immediate detoxification, or dramatic antioxidant shifts from oral capsules is weak to non-existent. What the research does support: liposomal glutathione at 250–500mg daily or IV glutathione at clinical doses can elevate plasma levels meaningfully. But those elevated levels translate to modest, gradual improvements in oxidative stress markers, not overnight transformations.

The most cost-effective approach for most people is not glutathione supplementation at all. It is supporting endogenous synthesis with N-acetylcysteine (NAC) at 600mg twice daily. NAC provides the rate-limiting substrate (cysteine) for intracellular glutathione production, bypassing the bioavailability problem entirely. Clinical trials show comparable plasma glutathione elevation from NAC as from oral GSH, at roughly one-third the cost. If budget matters and you are supplementing for general antioxidant support rather than a specific clinical indication, NAC is the more defensible choice.

For research applications requiring precise dosing and verifiable bioavailability, our team has found that working with high-purity peptide sources ensures consistency across batches. You can explore tools like Thymalin and see how peptide precision extends across the full research collection we provide.

The supplement industry overstates what oral glutathione can deliver at typical consumer doses. That does not mean it is useless. It means expectations must align with pharmacokinetics. Oral glutathione at properly dosed liposomal formulations works slowly and requires consistency. IV glutathione works predictably but requires clinical administration. NAC works reliably by supporting the pathway your cells already use. Choose the route that matches your goal, budget, and tolerance for delayed results.

If oral glutathione at 500–1000mg daily for three months produces no subjective or objective improvement, the problem is almost certainly absorption. Escalating the dose will not fix a bioavailability issue. Switching to liposomal or IV administration will. The ceiling for oral glutathione effectiveness is not dose-dependent beyond 1000mg. It is absorption-dependent, and absorption is determined by formulation chemistry, not quantity.